Karolinska Development AB (publ) (STO:KDEV)
Sweden · Delayed Price · Currency is SEK 0.2995
-0.0105 (-3.39%)
Jan 21, 2026, 5:29 PM CET
Karolinska Development AB Company Description
Karolinska Development AB (publ) is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies.
It seeks to invest in pharmaceutical research and development, medical research, medical innovations, healthcare technology, gene research and development, drug delivery technologies, biotechnology, and life science tools and service sectors.
The firm seeks to invest in the Nordic region with a focus on Sweden, Iceland, Norway, Finland, and Denmark.
It prefers to be a lead investor in its portfolio companies however does consider co-investments also.
It seeks to invest in up to five projects annually. Karolinska Development AB (publ) was founded in 2003 and is headquartered in Stockholm, Sweden.
Karolinska Development AB (publ)
| Country | Sweden |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Viktor Drvota |
Contact Details
Address: Nanna Svartz väg 6A Solna, 17165 Sweden | |
| Phone | 46 8 524 860 70 |
| Website | karolinskadevelopment.com |
Stock Details
| Ticker Symbol | KDEV |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0002190926 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Johan Dighed | Chief Legal Officer and Deputy Chief Executive Officer |
| Dr. Viktor Drvota M.D., Ph.D. | Chief Executive Officer |
| Hans Christopher Toll | Chief Financial Officer |
| Eva Montgomerie | Head of Accounting |
| Dr. John Öhd M.D., Ph.D. | Chief Scientific Officer and Venture Partner |
| Tse Ping | Senior Strategic Advisor |
| Mathias Frenzel | Investment Analyst |